Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24;9(12):2997-3001.
doi: 10.1182/bloodadvances.2024015164.

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Eleftheria Kampouri  1   2 , Patrick Flaherty  1 , Hu Xie  3 , Mandeep K Sekhon  1 , Clementine Chalal  1 , Terry L Stevens-Ayers  1 , Damian J Green  4   5 , Jordan Gauthier  3   5 , Mazyar Shadman  3   5 , Ailyn C Pérez-Osorio  6 , Keith R Jerome  1   6 , Wendy M Leisenring  3   7 , Michael J Boeckh  1   3   5 , Joshua A Hill  1   3   5
Affiliations

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Eleftheria Kampouri et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: E.K. reports advisory board participation with and received support for conferences from Merck. J.G. has served as ad hoc consultant and received honoraria from Sobi, Legend Biotech, Janssen, Kite Pharma, and MorphoSys; received research funding from Sobi, Juno Therapeutics (a Bristol Myers Squibb company), Celgene (a Bristol Myers Squibb company), and Angiocrine Bioscience; and participated in the independent data review committee for Century Therapeutics. M.S. has served as a consultant and participated in advisory boards, steering committees, or data safety monitoring committees for AbbVie, Genentech, AstraZeneca, Genmab, Janssen, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, and Merck; received research funding from Mustang Bio, Genentech, AbbVie, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, and Vincerx; has stock options in Koi Biotherapeutics; and reports employment with Bristol Myers Squibb (spouse). D.J.G. has served as an advisor and received research funding and royalties from Juno Therapeutics, a Bristol Myers Squibb company; served as an advisor and received research funding from Seattle Genetics, Janssen Biotech, and Bristol Myers Squibb; served as an advisor for GlaxoSmithKline, Celgene, Ensoma, and Legend Biotech; and received research funding from SpringWorks Therapeutics, Sanofi, and Cellectar Biosciences. M.J.B. has served as a consultant for Merck, Takeda, Symbio, Assembly Bio, AlloVir, and Moderna; received research funding from Merck and Moderna; and served as a consultant and had the option to acquire stock for Evrys Bio. J.A.H. has served as a consultant for Moderna, AlloVir, Gilead, Takeda, CSL Behring, and Karius, and received research funding from AlloVir, Gilead, Merck, and Takeda. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS within a year after CARTx stratified by any CMV reactivation and CMV reactivation ≥150 IU/mL. Cumulative incidence of (A) OS by 1 year in patients with and without CMV reactivation at any level occurring before 6 weeks after CARTx (65.0%; 95% CI, 34.1-84.2, vs 76.8%; 95% CI, 61.0-86.9) and (B) OS by 1 year in patients with and without CMV reactivation ≥150 IU/mL occurring before 6 weeks after CARTx (57.1%; 95% CI, 9.3-87.6, vs 75.4%; 95% CI, 61.2-85.1). HR from univariate Cox regression is shown on the plots. HR, hazard ratio.
Figure 2.
Figure 2.
Forest plots of multivariable Cox regression models for OM within 1 year after CARTx. Forest plots of models incorporating (A) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, CMV reactivation (any level) detected within 6 weeks of CARTx; (B) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and CMV reactivation (any level) detected within 6 weeks of CARTx; and (C) CAR T-cell target (CD19/CD20 vs BCMA), CRS and/or ICANS grade ≥2, and CMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. (D) CAR T-cell target (CD19/CD20 vs BCMA), corticosteroid use for >3 days, and csCMV reactivation ≥150 IU/mL detected within 6 weeks of CARTx. Survival analysis including data on 82 participants. CRS, cytokine release syndrome; HR, hazard ratio; ICANS, immune effector cell–associated neurotoxicity syndrome.
See this image and copyright information in PMC

References

    1. Márquez-Algaba E, Iacoboni G, Pernas B, et al. Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy. Transpl Cell Ther. 2022;28(12):851.e1–851.e8. - PubMed
    1. Chen G, Herr M, Nowak J, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108(2):615–620. - PMC - PubMed
    1. Solano de la Asunción C, Hernani R, Albert E, et al. Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored? Clin Microbiol Infect. 2023;29(8):1093–1095. - PubMed
    1. Lin RY, Anderson AD, Natori Y, et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024;8(14):3813–3822. - PMC - PubMed
    1. Kampouri E, Ibrahimi SS, Xie H, et al. Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin Infect Dis. 2024;78(4):1022–1032. - PMC - PubMed